#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thymic carcinoma Systemic scleroderma Epstein-Barr virus infection Mucopolysaccharidosis II Cytokine release syndrome Diffuse large B-cell lymphoma recurrent Meningitis meningococcal Fragile X syndrome Von Willebrand's disease Methylmalonic acidaemia Chemical burn Craniopharyngioma Chordoma Meningococcal immunisation Intracranial germ cell tumour More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome Prader-Willi syndrome – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Trials in Disease Alexander disease – Treatment Glomerulonephritis rapidly progressive – Treatment Mantle cell lymphoma stage II – Diagnostics Paroxysmal nocturnal haemoglobinuria – Diagnostics Anaplastic thyroid cancer Adrenogenital syndrome Focal segmental glomerulosclerosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cloxacillin Sodium Bp1.7881A Cldn6 Car-T(A) Fluconazole Histidine Gemtuzumab Ozogamicin Polydextrose Prednisolone Acetate Atomoxetine Sunvozertinib Blu-451 Arachis Hypogaea Flour Raxtozinameran Rbd4059 Fludrocortisone Acetate Vixarelimab Resmetirom Tiotropium Bromide Monohydrate Prednisone Acetate Ginisortamab More therapies…

    Learn about Your Condition

    Embolism Oropharyngeal cancer recurrent Stress urinary incontinence Thrombocytosis Mucous membrane pemphigoid Corticobasal degeneration Ependymoma malignant Anal fissure Coronary artery dissection Cachexia Pyoderma gangrenosum Biliary tract operation Lymphatic malformation Dementia Acute respiratory failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer stage III

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

    Recruiting

    1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    • Squamous cell carcinoma of lung
    Investigated Drugs:
    • BNT327
    France Italy Poland Spain

  • A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer stage IIIA
    Investigated Drugs:
    • Pemetrexed Disodium
    • BNT327
    • Carboplatin
    Germany Italy Poland Spain

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Cemiplimab
    • Docetaxel
    Hungary Poland Portugal Romania Spain

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cemiplimab
    Austria Estonia France Germany Ireland Italy +1

  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Pemetrexed Disodium
    • BNT327
    • Carboplatin
    Belgium Bulgaria France Germany Hungary Italy +3
1 2 3 … 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!